netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.04  Expand sub section  Beta-adrenoceptor blocking drugs
Atenolol 
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice
Green

Atenolol Tablet 25mg 
Atenolol Tablet 50mg 
Atenolol Tablet 100mg
Atenolol Oral Solution 25mg/5ml SF

1st line beta-blocker

 
Bisoprolol Fumarate

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Bisoprolol Fumarate Tablet 1.25mg
Bisoprolol Fumarate Tablet 2.5mg
Bisoprolol Fumarate Tablet 3.75mg
Bisoprolol Fumarate Tablet 5mg
Bisoprolol Fumarate Tablet 7.5mg
Bisoprolol Fumarate Tablet 10mg

 
   
Labetalol Hydrochloride

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Labetalol Hydrochloride Tablet 50mg 
Labetalol Hydrochloride Tablet 100mg 
Labetalol Hydrochloride Tablet 200mg 
Labetalol Hydrochloride Tablet 400mg 

Also licensed for Hypertension in Pregnancy

 
   
Metoprolol Tartrate

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Metoprolol Tartrate Tablet 50mg 
Metoprolol Tartrate Tablet 100mg 

 
   
Propranolol Hydrochloride

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Propranolol Hydrochloride Tablet 10mg 
Propranolol Hydrochloride Tablet 40mg
Propranolol Hydrochloride Tablet 80mg 
Propranolol Hydrochloride Tablet 160mg 
Propranolol Hydrochloride MR Capsule 80mg
Propranolol Hydrochloride MR Capsule 160mg
Propranolol Hydrochloride Oral Solution 5mg/5ml
Propranolol Hydrochloride Oral Solution 10mg/5ml
Propranolol Hydrochloride Oral Solution 40mg/5ml
Propranolol Hydrochloride Oral Solution 50mg/5ml

Prescribe MR capsules generically as more cost-effective(Applicable in Primary care only)

 
   
Nebivolol 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Nebivolol 2.5mg tablet (more cost-effective to use half a 5mg tablet)
Nebivolol 5mg tablet

Restriction: For patients who cannot tolerate Bisoprolol for heart failure

Does not offer any additional benefit over established beta blockers that are available at a lower aquisition cost.

 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary